CareLit · DOI-Nachweis · Pneumologie
Once-daily tiotropium Respimat® is well tolerated and efficacious over 52 weeks in Japanese patients with symptomatic asthma receiving inhaled corticosteroids (ICS)± long-acting β2-agonist (LABA): a randomized, double-blind, placebo-contro…
DOI 10.1055/s-0035-1544686
Bibliografische Angaben
Nachweis in CareLit
Autor:innenO Schmidt, K Ohta, M Ichinose, Y Tohda, M Engel, P Moroni-Zentgraf, S Kunimitsu, W Sakamoto, M Adachi
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Rationale: The present study evaluated long-term safety and efficacy of tiotropium Respimat® (tioR) in Japanese patients with moderate to severe symptomatic asthma, despite ICS ± LABA. Methods: In thisPhase III trial across 54 Japanese centers (NCT01340209), patients were randomized to receive evening tioR 5 µg, 2.5 µg, or placebo (PBO), for 52 weeks. Eligible patients: seven-question Asthma Control Questionnaire me…
Zitieren
Zitierempfehlung
O Schmidt, K Ohta, M Ichinose, Y Tohda, M Engel, P Moroni-Zentgraf, S Kunimitsu, W Sakamoto, M Adachi (2015) Once-daily tiotropium Respimat® is well tolerated and efficacious over 52 weeks in Japanese patients with symptomatic asthma receiving inhaled corticosteroids (ICS)± long-acting β2-agonist (LABA): a randomized, double-blind, placebo-controlled study. Pneumologie (02). https://doi.org/10.1055/s-0035-1544686
Mit CareLit weiterarbeiten